ClinicalTrials.gg
RecruitingNCT04842071Updated Feb 7, 2024

18F-sodium Fluoride (NaF) PET to Replace Bone Scintigraphy: Safety and Efficacy Assessment

A Phase 3 interventional study of 18F-sodium fluoride in Bone Cancer, Articular Disease and Infectious Disease, sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke. Recruiting at 2 sites in Canada. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Phase 3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 13 years 3 months after the study started (first participant enrolled Jan 2008, registered Apr 2021).
  • Started Jan 2008; still recruiting 18 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,500
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Bone Neoplasms with a site in Canada — 2 open to participants now, 4 under way, 1 of them phase 3. Bone Neoplasms · Canada.

Planned enrollment
Largest of 17
2,500 · median 128
Started
2008
with 2 others
Phase 3
5 of 18
1 open now
Registered
17th of 18
by date
Lead sponsor
1 of 18
Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Among the 18 studies in Bone Neoplasms with a site in Canada, this one has the largest planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2008, is one of 5 in phase 3, and was the 17th registered.

Bone Neoplasms

259 studies on the registry are indexed under Bone Neoplasms; 70 are open to participants now.

Browse Bone Neoplasms studies →

Open to participants now

2 of the 18 studies in Bone Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 54 Bone Neoplasms studies recruiting now, 35 (65%) set no upper age limit and 13 (24%) stop at 75 or younger; 25 take children under 18; 4 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Bone Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

18F-sodium fluoride (18F-NaF) was already investigated numerous times in the last 40 years as a PET alternative to standard 99m-technetium-derived bone scintigraphy. However, lack of universal tracer availability and higher costs contributed to the failure of 18F-NaF to systematically supplant bone scintigraphy as a standard of care.

Recently, an isotope shortage crisis occurred and evidenced the need to have non-reactor-derived alternatives for many nuclear medicine procedures, including bone scintigraphy. Since 18F-NaF is cyclotron-produced, it could become a necessary alternative to bone scintigraphy in case of another worldwide isotope shortage.

The study aims to evaluate the safety profile of 18F-NaF injection. Moreover, a patient registry will be compiled in order to perform sub-studies on 18F-NaF diagnostic performance on diverse bone and articular diseases.

03

Conditions studied

  • Bone Cancer
  • Articular Disease
  • Infectious Disease

Keywords

  • 18F-NaF
  • Bone scintigraphy
  • bone diseases
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients for whom a 99mTc-biphosphonate bone scintigraphy is indicated;
  • Pediatric patients for whom a 99mTc-biphosphonate bone scintigraphy is indicated for oncologic or infectious reasons
  • Able to tolerate supine position
  • Written consent

Exclusion criteria

Exclusion Criteria:

  • Healthy subjects
  • Pregnancy
  • Unable of maintaining supine position for more than 15 minutes
  • Refusal to sign the consent form
  • Known allergy or to 18F-NaF or any of its constituants.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,500 participants (estimated)

Study arms

  • Experimental
    18F-NaF eligible patients

    Eligibility for 18F-NaF PET scans is the same than for bone scintigraphy routinely prescribed in the clinic.

    Diagnostic Test: 18F-sodium fluoride

Interventions

  • Diagnostic test18F-sodium fluoride

    Intravenous injection of 4 MBq/kg for pediatric patients, or 5 MBq/kg for adult patients (maximum of 555 MBq), followed by a 45 minutes waiting time. Patients is then placed in supine position in a PET/CT scanner for a duration of no more than 30 minutes.

    Also known as: 18F-NaF

06

What researchers measure

Primary outcomes

  1. Safety profile of 18F-NaF

    A registry monitoring eventual adverse effects for this radiopharmaceutical agent will be compiled. Usual procedures will be applied to divulgate any serious adverse effects.

    Time frame: 17 years

  2. Efficacy profile of 18F-NaF compared to 99mTc-biphosphonate bone scintigraphy

    Using the patient registry, and in the eventual sub-studies to come, the diagnostic performance of 18F-NaF-PET will be compared to similar available imaging tests, most notably 99mTc-biphosphonate bone scintigraphy.

    Time frame: 17 years

  3. Correlate 18F-NaF PET images with pathology reports

    Pathology data from the diverse conditions eligible for the 18F-NaF PET scan will be also monitored when available. Prognostic value from the imaging data will be compared with those obtained from the pathology.

    Time frame: 17 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2008 (actual). Primary completion is estimated for Dec 2025, 215 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2021
First posted
Apr 13, 2021
StartActual
Jan 1, 2008
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04842071
Lead sponsor
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Responsible party
Dr Éric E Turcotte, MD (Head of clinical research, CIMS, CRCHUS, Centre de recherche du Centre hospitalier universitaire de Sherbrooke) — Principal investigator
First posted
Apr 13, 2021
Start date
Jan 1, 2008
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Feb 7, 2024

Study contacts

Stéphanie Dubreuil
Contact
stephanie.dubreuil2@usherbrooke.ca
819-346-1110 ext. 16617
Éric E Turcotte, MD
principal investigator · Université de Sherbrooke, Centre de Recherche du CHUS

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion